Wockhardt is currently trading at Rs. 458.90, up by 18.65 points or 4.24% from its previous closing of Rs. 440.25 on the BSE.
The scrip opened at Rs. 462.25 and has touched a high and low of Rs. 462.25 and Rs. 420.55 respectively. So far 7, 98,000 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 2166.05 on 12-Mar-2013 and a 52 week low of Rs. 344.15 on 08-Aug-2013.
Last one week high and low of the scrip stood at Rs. 440.25 and Rs. 344.15 respectively. The current market cap of the company is Rs. 5,028 crore.
The promoters holding in the company stood at 73.54% while Institutions and Non-Institutions held 13.62% and 12.71% respectively.
Wockhardt has received a ‘warning letter’ from USFDA for its Waluj facility, which lists the observations made during the inspection. The company has already initiated several corrective actions to resolve the same. The company continues to cooperate with USFDA to resolve the issues at the earliest. The company had earlier received an 'import alert' from USFDA on one of its manufacturing unit located in Waluj near Aurangabad on May 24, 2013.
Wockhardt is one of the few companies with end to end integrated capabilities for its products, starting with the manufacture of the oral and sterile API’s, the dose forms and marketing through wholly owned subsidiary in the US, enabling the company to capture maximum value.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1861.70 |
Dr. Reddys Lab | 1389.35 |
Cipla | 1506.15 |
Lupin | 2228.00 |
Zydus Lifesciences | 972.70 |
View more.. |